SpaceX Successfully Tests Redesigned Starship Ahead of Potential Landmark IPO HDFC Bank Shares Dip 2 as Internal Vigilance Probe Into 45 Crore MSRDC Interest Payments Emerges TeraWulf WULF in Focus Assessing LongTerm Potential Among LowPriced Stocks JM Smucker SJM Faces Lower Forward Estimates After JPMorgan Price Target Cut ADP Private Payrolls Rise 109000 in April Surpassing Expectations Signaling Labor Market Resilience London Stock Exchange Group Reports Income Growth Driven by Tradeweb Performance HAE Q1 2026 Earnings EPS Slightly Beats Estimates Shares Rally Alpha Tau Medical DRTS Q1 2026 Earnings Wider Loss Surprises Markets Stock Slips PGEN Q1 2026 Earnings NarrowerThanExpected Loss Highlights Cost Discipline Amid Zero Revenue BVN Q4 2025 Earnings Strong EPS Surprise Driven by Operational Gains ARE Q1 2026 Earnings Massive EPS Surprise of 1459 Drives Positive Stock Reaction IVVD Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Focuses on Pipeline Progress Nurix Therapeutics NRIX Rallies 230 as Buyers Test Resistance Near 1867 Ceragon Networks CRNT Holds Near Support as Tight Range Persists National Storage Affiliates Trust NSA Gains 117 as Volume Confirms Breakout From Support Forestar Group Inc FOR Slips 107 as Traders Weigh Key Support and Resistance Levels AgEagle Aerial Systems UAVS Surges 5 as Shares Test Key Resistance at 107 Nuclear Startup Newcleo to Go Public on Nasdaq at 24 Billion Valuation NNOX Q4 2025 Earnings WiderThanExpected Loss as Revenue Details Remain Scarce SolGel Technologies SLGL Retraces 291 as Shares Approach Key Support Level Este Lauder and Puig Terminate Merger Discussions Shares Surge in AfterHours Trading Colliers International CIGI Q1 2026 Earnings EPS Misses Estimates Amid Challenging Market Conditions CRVS Q1 2026 Earnings WiderthanExpected Loss Offset by Pipeline Progress WPM Q1 2026 Earnings Slight EPS Beat Amid Stable Precious Metals Market TAOP Q2 2011 Earnings EPS Misses Estimates but Stock Rallies 881 BWX Technologies Q1 2026 Earnings Strong EPS Beat Overshadowed by Modest Share Decline BLTE Q4 2025 Earnings WiderthanExpected Loss as PreRevenue Biotech Remains Focused on Clinical Development